Literature DB >> 20547449

Categorization and impact of pulmonary hypertension in patients with advanced COPD.

Michael J Cuttica1, Ravi Kalhan, Oksana A Shlobin, Shahzad Ahmad, Mark Gladwin, Roberto F Machado, Scott D Barnett, Steven D Nathan.   

Abstract

INTRODUCTION: The functional significance of pulmonary hypertension (PH) in COPD is unclear. The purpose of the study was to define the prevalence, severity and associated functional impact of PH in patients with severe COPD listed for lung transplant.
METHODS: A retrospective review of the Organ Procurement and Tissue Network (OPTN) database between 1997 and 2006 for patients with the primary diagnosis of COPD. Baseline demographics, hemodynamics, pulmonary function tests, six minute walk distance test (6MWD) and pre-transplant survival data was analyzed.
RESULTS: 4930 patients with COPD had evaluable right heart catheterization data (RHC). PH was present in 30.4%, with pulmonary venous hypertension (PVH) accounting for an additional 17.2% of patients. Patients with pulmonary hypertension walked an average of 28 m less than those with normal hemodynamics. Normal hemodynamics group: 261 ± 104 m, PH; 238 ± 106 m (p < 0.01), PVH: 228 ± 104 m (p < 0.05). In a multivariable analysis, the mean pulmonary artery pressure (β = -1.33; p = 0.01) was an independent predictor of a reduced 6MWD, as were forced vital capacity (β = 1.48; p < 0.001) and patient age (β = -1.91; p < 0.001). Both PH (HR 1.23 95%CI [1.01-1.50]) and PVH (HR 1.35 95%CI [1.11-1.65]) were shown to be independent risk factors for mortality on the waiting list, even after adjustment for age sex, race, BMI, lung function, severity of illness and diabetes (PH: HR 1.27; 95%CI [1.04-1.55], PVH: HR 1.40; 95%CI [1.13-1.73]).
CONCLUSION: PH is common in advanced COPD and is associated with functional impairment and an increased mortality risk. Stratification by RHC determined pulmonary hemodynamics appears important in distinguishing distinct clinical phenotypes.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20547449     DOI: 10.1016/j.rmed.2010.05.009

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  50 in total

1.  CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD.

Authors:  Anand S Iyer; J Michael Wells; Sonia Vishin; Surya P Bhatt; Keith M Wille; Mark T Dransfield
Journal:  Chest       Date:  2014-04       Impact factor: 9.410

Review 2.  Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery.

Authors:  Isabelle Opitz; Silvia Ulrich
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 3.  Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.

Authors:  Kurt R Stenmark; Rubin M Tuder; Karim C El Kasmi
Journal:  J Appl Physiol (1985)       Date:  2015-04-30

4.  Electrocardiographic differences between COPD patients evaluated for lung transplantation with and without pulmonary hypertension.

Authors:  Laith Alkukhun; Manfred Baumgartner; Marie Budev; Raed A Dweik; Adriano R Tonelli
Journal:  COPD       Date:  2014-07-01       Impact factor: 2.409

5.  Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.

Authors:  Hossein A Ghofrani; Gerd Staehler; Ekkehard Grünig; Michael Halank; Veselin Mitrovic; Sigrun Unger; Wolfgang Mueck; Reiner Frey; Friedrich Grimminger; Ralph T Schermuly; Juergen Behr
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

6.  The effect of pulmonary hypertension on aerobic exercise capacity in lung transplant candidates with advanced emphysema.

Authors:  Yochai Adir; Jacob E Ollech; Baruch Vainshelboim; Yael Shostak; Arie Laor; Mordechai R Kramer
Journal:  Lung       Date:  2015-03-07       Impact factor: 2.584

Review 7.  Pulmonary hypertension associated with lung diseases and hypoxemia.

Authors:  Michael J Cuttica
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

8.  Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with chronic obstructive pulmonary disease.

Authors:  Harry Karmouty-Quintana; Tingting Weng; Luis J Garcia-Morales; Ning-Yuan Chen; Mesias Pedroza; Hongyan Zhong; Jose G Molina; Raquel Bunge; Brian A Bruckner; Yang Xia; Richard A Johnston; Matthias Loebe; Dewan Zeng; Harish Seethamraju; Luiz Belardinelli; Michael R Blackburn
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

9.  JNK2 up-regulates hypoxia-inducible factors and contributes to hypoxia-induced erythropoiesis and pulmonary hypertension.

Authors:  Marc A Sala; Cong Chen; Qiao Zhang; Hanh Chi Do-Umehara; Wenjiao Wu; Alexander V Misharin; Gregory B Waypa; Deyu Fang; G R Scott Budinger; Shuwen Liu; Navdeep S Chandel; Paul T Schumacker; Jacob I Sznajder; Jing Liu
Journal:  J Biol Chem       Date:  2017-11-08       Impact factor: 5.157

10.  Right Atrium Volume Index in Patients with Secondary Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease.

Authors:  Lucia Agoston-Coldea; Dana Petrovai; Isabella Mihalcea; Radu Revnic; Teodora Mocan; Silvia Lupu
Journal:  Acta Cardiol Sin       Date:  2015-07       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.